| SC 13G | 2021-03-15 | COMMODORE CAPITAL LP | Satsuma Pharmaceuticals, Inc. | 2,119,245 | 6.7% | EDGAR |
| SC 13D/A | 2021-03-02 | RA CAPITAL MANAGEMENT, L.P. | Satsuma Pharmaceuticals, Inc. | 5,914,252 | 18.8% | EDGAR |
| SC 13G/A | 2021-02-16 | CITADEL ADVISORS LLC | Satsuma Pharmaceuticals, Inc. | - | 2.0% | EDGAR |
| SC 13G/A | 2021-02-12 | MORGAN STANLEY | Satsuma Pharmaceuticals, Inc. | 993,623 | 5.7% | EDGAR |
| SC 13G | 2020-12-18 | MORGAN STANLEY | Satsuma Pharmaceuticals, Inc. | 881,438 | 5.1% | EDGAR |
| SC 13G/A | 2020-12-04 | Osage University Partners III, LP | Satsuma Pharmaceuticals, Inc. | 0 | 0.0% | EDGAR |
| SC 13G/A | 2020-10-09 | WELLINGTON MANAGEMENT GROUP LLP | Satsuma Pharmaceuticals, Inc. | 0 | 0.0% | EDGAR |
| SC 13G/A | 2020-08-10 | WELLINGTON MANAGEMENT GROUP LLP | Satsuma Pharmaceuticals, Inc. | 1,343,168 | 7.7% | EDGAR |
| SC 13G/A | 2020-02-14 | CAXTON CORP | Satsuma Pharmaceuticals, Inc. | 659,252 | 3.8% | EDGAR |
| SC 13G/A | 2020-02-14 | CITADEL ADVISORS LLC | Satsuma Pharmaceuticals, Inc. | - | 5.9% | EDGAR |
| SC 13G | 2020-02-13 | TPG Group Holdings (SBS) Advisors, Inc. | Satsuma Pharmaceuticals, Inc. | 1,885,939 | 10.6% | EDGAR |
| SC 13G/A | 2020-01-27 | WELLINGTON MANAGEMENT GROUP LLP | Satsuma Pharmaceuticals, Inc. | 2,341,211 | 13.5% | EDGAR |
| SC 13G | 2019-11-27 | Osage University Partners III, LP | Satsuma Pharmaceuticals, Inc. | 935,058 | 5.4% | EDGAR |
| SC 13G | 2019-10-21 | CAXTON CORP | Satsuma Pharmaceuticals, Inc. | 870,820 | 5.1% | EDGAR |
| SC 13G | 2019-10-10 | WELLINGTON MANAGEMENT GROUP LLP | Satsuma Pharmaceuticals, Inc. | 2,405,295 | 13.6% | EDGAR |
| SC 13G | 2019-09-23 | CITADEL ADVISORS LLC | Satsuma Pharmaceuticals, Inc. | - | 5.8% | EDGAR |
| SC 13D | 2019-09-17 | RA CAPITAL MANAGEMENT, LLC | Satsuma Pharmaceuticals, Inc. | 4,681,858 | 28.2% | EDGAR |